First-in-Man Open Clinical Trial of a Combined rdESAT-6 and rCFP-10 Tuberculosis Specific Skin Test Reagent
Figure 1
Participants were screened from −28 to −3 days before inclusion. The injections were given at day 0 and day 42 or on day 0 and day 84. Group A and B received 0.01 µg of the investigational skin test antigen. Group C and D received 0.1 µg. All volunteers completed a final follow-up visit 28 days after the last injection.